Ocular Hypotensive Efficacy of Bimatoprost 0.03% and Travoprost 0.004% in Patients with Glaucoma or Ocular Hypertension

Survey of Ophthalmology

Volumn 49, Issue 2 SUPPL. 1, 2004, Pages

  Cantor, Louis B ^a,b   WuDunn, Darrell ^a   Cortes, Arnold ^a   Hoop, Joni ^a   Knotts, Stephenie ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Bimatoprost; Glaucoma; Intraocular pressure; Ocular hypertension; Target pressures; Travoprost

Indexed keywords

BIMATOPROST; TRAVOPROST;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONJUNCTIVAL HYPEREMIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GLAUCOMA; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR HYPOTENSION; MALE; OPEN ANGLE GLAUCOMA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

AMIDES; ANTIHYPERTENSIVE AGENTS; CLOPROSTENOL; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG EVALUATION; FEMALE; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; LIPIDS; MALE; MIDDLE AGED; OCULAR HYPERTENSION; OPHTHALMIC SOLUTIONS; PILOT PROJECTS; PROSPECTIVE STUDIES;

EID: 1542328114     PISSN: 00396257     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.survophthal.2003.12.015     Document Type: Article

References (13)

1. The Advanced Glaucoma Intervention Study (AGIS). 7. The relationship between control of intraocular pressure and visual field deterioration. The AGIS Investigators. Am J Ophthalmol. 130:2000;429-440.
2. Abelson M.B., Mroz M., Rosner S.A. Multicenter, open-label evaluation of hyperemia associated with use of bimatoprost in adults with open-angle glaucoma or ocular hypertension. Adv Ther. 20:2003;1-13.
3. Brubaker R.F. Mechanism of action of bimatoprost (Lumigan). Surv Ophthalmol. 45:(Suppl 4):2001;S347-S351.
4. DuBiner H., Cooke D., Dirks M. Efficacy and safety of bimatoprost in patients with elevated intraocular pressure: a 30-day comparison with latanoprost. Surv Ophthalmol. 45:(Suppl 4):2001;S353-S360.
5. Gandolfi S., Simmons S.T., Sturm R. Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension. Adv Ther. 18:2001;110-121.
6. Heijl A., Leske C., Bengtsson B. Reduction of intraocular pressure and glaucoma progression: results from the early manifest glaucoma trial. Arch Ophthalmol. 120:2002;1268-1279.
7. Higgenbotham E., Schuman J., Goldberg I. One-year, randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertension. Arch Ophthalmol. 120:2002;1286-1293.
8. Mao L.K., Stewart W.C., Shields M.B. Correlation between intraocular pressure control and progressive glaucomatous damage in primary open-angle glaucoma. Am J Ophthalmol. 111:1991;51-55.
9. Netland P.A., Landry T., Sullivan E.K. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol. 132:2001;472-484.
10. Noecker R.J., Dirks M.S., Choplin N.T. A six-month randomized clinical trial comparing the IOP-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am J Ophthalmol. 135:2003;55-63.
11. Orengo-Nania S., Landry T., Von Tress M. Evaluation of travoprost as adjunctive therapy in patients with uncontrolled intraocular pressure while using timolol 0.5%. Am J Ophthalmol. 132:2001;860-868.
12. Parrish R.K., Palmberg P., Sheu W.-P. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol. 135:2003;688-703.
13. Sherwood M., Brandt J. Six-month comparison of bimatoprost once-daily and twice-daily with timolol twice-daily in patients with elevated intraocular pressure. Surv Ophthalmol. 45:(Suppl 4):2001;S361-S368.